Skip to main content

Table 1 Open clinical trials of CAR-T-cell therapy for patients with CLL

From: Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

ClinicalTrials ID

Trial title/description

Target

NCT02640209

Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)

CD19

NCT02644655

Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

CD19

NCT02456350

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

CD19

NCT03076437

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

CD19

NCT01865617

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

CD19

NCT02933775

CD19-redirected Autologous Cells (CAR-CD19 T Cells)

CD19

NCT02672501

A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

CD19

NCT01853631

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

CD19

NCT03110640

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

CD19

NCT01747486

CD19 Redirected Autologous T Cells

CD19

NCT03085173

A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

CD19

NCT02685670

Competitive Transfer of #CD19-TCRz-CD28 and #CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma

CD19

NCT02782351

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

CD19

NCT00881920

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Kappa

NCT02050347

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

CD19

NCT02963038

CAR T Cells for Refractory B Cell Malignancy

CD19

NCT03068416

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

CD19

NCT03166878

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

CD19

NCT03448393

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

CD19/CD22

NCT03191773

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

CD19

NCT02132624

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial

CD19

NCT03277729

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

CD20

NCT02851589

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

CD19

NCT02819583

CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

CD19

NCT03302403

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

CD19

NCT02706392

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies

ROR1

NCT01626495

Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma

CD19

NCT01475058

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

CD19

NCT03331198

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)

CD19

NCT01593696

Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

CD19

NCT03436771

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

CD19

NCT01864889

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19

CD19

NCT03050190

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

CD19